证券代码：688068 证券简称：热景生物 公告编号：2025-089 北京热景生物技术股份有限公司 2025年第五次临时股东会决议公告 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 12 月 17 日 （二） 股东会召开的地点：北京市大兴区中关村科技园区大兴生物医药产业基 地庆丰西路 55 号公司三层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 | 1、出席会议的股东和代理人人数 | 223 | | --- | --- | | 普通股股东人数 | 223 | | 2、出席会议的股东所持有的表决权数量 | 34,491,099 | | 普通股股东所持有表决权数量 | 34,491,099 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 40.0069 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

2025 年第五次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于北京热景生物技术股份有限公司 北京德恒律师事务所 关于北京热景生物技术股份有限公司 2025 年第五次临时股东会的法律意见 北京德恒律师事务所 关于北京热景生物技术股份有限公司 2025年第五次临时股东会的 法律意见 德恒 01G20250768 号 致：北京热景生物技术股份有限公司 北京德恒律师事务所（以下简称"本所"）受北京热景生物技术股份有限公 司（以下简称"公司"）委托，本所指派律师（以下简称"本所承办律师"）出 席了公司2025年第五次临时股东会（以下简称"本次股东会"），对公司本次股 东会的召集与召开程序、出席会议人员的资格与召集人的资格、会议表决程序与 表决结果等有关事项出具见证意见。 本法律意见根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）等有关法律、法规和 规范性文件，以及《北京热景生物技术股份有限公司章程》（以下简称"《公司 ...

从资金流向上来看，当日医疗器械板块主力资金净流出3.48亿元，游资资金净流入3406.7万元，散户资 金净流入3.14亿元。医疗器械板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 证券之星消息，12月16日医疗器械板块较上一交易日下跌0.93%，热景生物领跌。当日上证指数报收于 3824.81，下跌1.11%。深证成指报收于12914.67，下跌1.51%。医疗器械板块个股涨跌见下表： ...

Quantitative Factors and Construction Methods - **Factor Name**: Large Order Transaction Amount Ratio **Construction Idea**: This factor captures the buying behavior of large funds by analyzing the proportion of large order transaction amounts relative to the total daily transaction amount[7] **Construction Process**: 1. Use tick-by-tick transaction data to identify buy and sell orders based on the sequence numbers of bids and asks 2. Filter transactions by order size to identify large orders 3. Calculate the proportion of large buy order transaction amounts to the total daily transaction amount **Formula**: $ \text{Large Order Transaction Amount Ratio} = \frac{\text{Large Buy Order Transaction Amount}}{\text{Total Daily Transaction Amount}} $ **Evaluation**: This factor effectively reflects the buying behavior of large funds and provides insights into market dynamics[7] - **Factor Name**: Net Active Buy Amount Ratio **Construction Idea**: This factor measures the active buying behavior of investors by analyzing the net active buy amount as a proportion of the total daily transaction amount[7] **Construction Process**: 1. Use tick-by-tick transaction data to classify each transaction as either active buy or active sell based on the buy/sell indicator 2. Calculate the net active buy amount by subtracting the active sell amount from the active buy amount 3. Compute the proportion of the net active buy amount to the total daily transaction amount **Formula**: $ \text{Net Active Buy Amount Ratio} = \frac{\text{Active Buy Amount} - \text{Active Sell Amount}}{\text{Total Daily Transaction Amount}} $ **Evaluation**: This factor provides a clear representation of investors' active buying behavior and is useful for tracking market sentiment[7] --- Factor Backtesting Results - **Large Order Transaction Amount Ratio**: - Top 5 stocks with the highest 5-day average values: 1. *Zaisen Technology (603601.SH)*: 91.4%, time-series percentile: 99.6%[9] 2. *Annie Shares (002235.SZ)*: 91.2%, time-series percentile: 98.4%[9] 3. *Kangxin New Materials (600076.SH)*: 87.9%, time-series percentile: 99.6%[9] 4. *Guangtian Group (002482.SZ)*: 87.6%, time-series percentile: 100.0%[9] 5. *Zhongtai Chemical (002092.SZ)*: 87.5%, time-series percentile: 100.0%[9] - **Net Active Buy Amount Ratio**: - Top 5 stocks with the highest 5-day average values: 1. *Hot Scene Biology (688068.SH)*: 15.9%, time-series percentile: 100.0%[10] 2. *Lanxiao Technology (300487.SZ)*: 14.5%, time-series percentile: 100.0%[10] 3. *Yilian Technology (301631.SZ)*: 14.0%, time-series percentile: 100.0%[10] 4. *Xiamen Bank (601187.SH)*: 14.0%, time-series percentile: 99.2%[10] 5. *Huamao Technology (603306.SH)*: 13.1%, time-series percentile: 99.6%[10] --- Additional Factor Testing Results - **Large Order Transaction Amount Ratio for Broad-Based Indices**: - *Shanghai Composite Index*: 5-day average: 73.0%, percentile: 59.0%[12] - *CSI 300*: 5-day average: 72.0%, percentile: 33.6%[12] - *ChiNext Index*: 5-day average: 71.4%, percentile: 14.8%[12] - **Net Active Buy Amount Ratio for Broad-Based Indices**: - *Shanghai Composite Index*: 5-day average: 0.8%, percentile: 7.8%[12] - *CSI 300*: 5-day average: 2.6%, percentile: 4.9%[12] - *ChiNext Index*: 5-day average: 3.5%, percentile: 2.5%[12] - **Large Order Transaction Amount Ratio for Industries**: - *Non-Bank Financials*: 5-day average: 78.5%, percentile: 95.9%[13] - *Steel*: 5-day average: 78.2%, percentile: 43.9%[13] - *Electric Power and Utilities*: 5-day average: 77.6%, percentile: 13.9%[13] - **Net Active Buy Amount Ratio for Industries**: - *Non-Bank Financials*: 5-day average: 6.3%, percentile: 0.8%[13] - *Electric Power and Utilities*: 5-day average: 1.8%, percentile: 1.6%[13] - *Steel*: 5-day average: 1.4%, percentile: 9.4%[13] - **Large Order Transaction Amount Ratio for ETFs**: - Top ETF: *Guotai Zhongzheng A500 ETF (159338.SZ)*: 91.5%, percentile: 20.1%[15] - **Net Active Buy Amount Ratio for ETFs**: - Top ETF: *Guotai SSE 10-Year Treasury Bond ETF (511260.SH)*: 25.9%, percentile: 87.7%[16]

Group 1 - The core point of the article is that the CSI Medical Index (399989) closed at 6769.62 points on December 15, experiencing a decline of 0.96% with a trading volume of 16.41 billion yuan and a turnover rate of 1.13% [1] - Among the constituent stocks of the CSI Medical Index, 17 stocks rose, with Dabo Medical leading the gain at 4.68%, while 32 stocks fell, with Rejing Biotech leading the decline at 5.72% [1] - The net outflow of main funds from the CSI Medical Index constituent stocks totaled 587 million yuan, while retail investors saw a net inflow of 537 million yuan [2] Group 2 - The CSI Medical Index underwent adjustments in the last 10 days, adding 6 new stocks and removing 6 stocks from its constituents [2]

Core Viewpoint - The medical device sector experienced a decline of 0.26% on December 15, with Hejing Bio leading the drop, while the Shanghai Composite Index fell by 0.55% and the Shenzhen Component Index decreased by 1.1% [1] Group 1: Market Performance - The medical device sector's decline was noted at 0.26% on the previous trading day [1] - The Shanghai Composite Index closed at 3867.92, down 0.55% [1] - The Shenzhen Component Index closed at 13112.09, down 1.1% [1] Group 2: Capital Flow - The medical device sector saw a net inflow of main funds amounting to 52.76 million yuan [2] - Retail investors contributed a net inflow of 52.48 million yuan, while speculative funds experienced a net outflow of 105 million yuan [2]

Group 1 - The report highlights the recent performance of various industries, with notable gains in sectors such as non-ferrous metals, electronics, and power equipment, while retail and real estate sectors faced declines [1][1][1] - The central economic work conference emphasized the importance of technological breakthroughs and supply-demand optimization, indicating a shift towards quality improvement in economic growth [11][12][19] - The commercial aerospace sector is experiencing significant growth, with the establishment of a dedicated regulatory body and a notable increase in the commercial aerospace index, which has risen by 46.52% since April 7 [47][48] Group 2 - The report indicates a seasonal recovery in social financing, with November seeing an increase of 24,885 billion yuan, driven primarily by government bond issuance [4][7] - The credit environment is showing signs of marginal improvement, particularly in corporate loans, which increased by 6,100 billion yuan in November, reflecting a recovery in demand [5][6] - The report notes that the retail sector is undergoing a transformation, with a focus on quality, as highlighted by the Ministry of Commerce's emphasis on retail quality upgrades [1][1][1] Group 3 - The report discusses the rising interest in inquiry transfers, which have seen a significant increase in both project numbers and transfer scale, indicating a growing trend in the market [51][52] - The technology sector is expected to remain a key focus, with upcoming events such as the Volcano Engine FORCE conference anticipated to showcase advancements in AI and cloud services [56]

Group 1 - The core transaction of the company involved a block trade on December 12, with a volume of 20,700 shares and a transaction amount of 4.1731 million yuan, at a price of 201.60 yuan per share [2] - In the last three months, the company has recorded a total of two block trades, with a cumulative transaction amount of 13.2882 million yuan [3] - The company's closing price on December 12 was 201.60 yuan, reflecting a 3.00% increase, with a daily turnover rate of 3.99% and a total transaction amount of 728 million yuan [3] Group 2 - The latest margin financing balance for the company is 165 million yuan, which has decreased by 13.293 million yuan over the past five days, representing a decline of 7.45% [4] - The company, Beijing Hotgen Biotech Co., Ltd., was established on June 23, 2005, with a registered capital of 92.70794 million yuan [4]

北京热景生物技术股份有限公司 2025 年第五次临时股东会会议资料 证券代码：688068 证券简称：热景生物 北京热景生物技术股份有限公司 2025 年第五次临时股东会会议资料 2025 年 12 月 | 目 录 | 1 | | --- | --- | | 2025 年第五次临时股东会会议须知 | 2 | | 2025 年第五次临时股东会会议议程 | 4 | | 2025 年第五次临时股东会会议议案 | 6 | 北京热景生物技术股份有限公司 2025 年第五次临时股东会会议资料 北京热景生物技术股份有限公司 2025 年第五次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会议的 顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股 东会规则》以及《北京热景生物技术股份有限公司章程》《北京热景生物技术股份有 限公司股东会议事规则》等相关规定，北京热景生物技术股份有限公司（以下简称 "公司"）特制定本次股东会会议须知： 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工作人员 将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 ...

Group 1 - Haichuang Pharmaceutical increased by over 10% [1] - Frontier Biotech rose by over 8% [1] - Yuekang Pharmaceutical, Rejing Biotech, Huisheng Biotech, and Zhongsheng Pharmaceutical also experienced gains [1]